CR20140361A - Inhibidores de pde9 con estructura básica de imidazotriazinona - Google Patents

Inhibidores de pde9 con estructura básica de imidazotriazinona

Info

Publication number
CR20140361A
CR20140361A CR20140361A CR20140361A CR20140361A CR 20140361 A CR20140361 A CR 20140361A CR 20140361 A CR20140361 A CR 20140361A CR 20140361 A CR20140361 A CR 20140361A CR 20140361 A CR20140361 A CR 20140361A
Authority
CR
Costa Rica
Prior art keywords
imidazotriazinona
basic structure
pde9 inhibitors
inhibitors
pde9
Prior art date
Application number
CR20140361A
Other languages
English (en)
Inventor
Niels Svenstrup
Klaus Baek Simonsen
Lars Kyhn Rasmussen
Karsten Juhl
Morten Langgard
Kate Wen
Yazhou Wang
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CR20140361A publication Critical patent/CR20140361A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a compuestos, que son inhibidores de la enzima PDE9. La invención proporciona una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de un compuesto de la invención y un portador farmacéuticamente aceptable. La presente invención también proporciona procesos para preparar compuestos de fórmula (I).
CR20140361A 2012-01-26 2014-07-24 Inhibidores de pde9 con estructura básica de imidazotriazinona CR20140361A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2012070718 2012-01-26
CN2012080208 2012-08-16
PCT/EP2013/051451 WO2013110768A1 (en) 2012-01-26 2013-01-25 Pde9 inhibitors with imidazo triazinone backbone

Publications (1)

Publication Number Publication Date
CR20140361A true CR20140361A (es) 2014-11-11

Family

ID=47603775

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140361A CR20140361A (es) 2012-01-26 2014-07-24 Inhibidores de pde9 con estructura básica de imidazotriazinona

Country Status (15)

Country Link
US (3) US9434733B2 (es)
EP (2) EP2807163B1 (es)
CN (2) CN104093720B (es)
AP (1) AP2014007820A0 (es)
AU (2) AU2013213603B2 (es)
BR (1) BR112014018199A8 (es)
CO (1) CO7020913A2 (es)
CR (1) CR20140361A (es)
DO (1) DOP2014000175A (es)
EC (1) ECSP14015609A (es)
HK (1) HK1199879A1 (es)
MX (1) MX351582B (es)
PH (1) PH12014501695B1 (es)
SG (1) SG11201403909RA (es)
WO (1) WO2013110768A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011305568B2 (en) 2010-09-20 2015-12-10 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
EP4640259A3 (en) 2010-10-08 2025-11-12 Fisher & Paykel Healthcare Limited Mask seal assembly
CN106905324B (zh) 2011-10-10 2018-09-25 H.隆德贝克有限公司 具有咪唑并吡嗪酮骨架的pde9抑制剂
CN104093720B (zh) 2012-01-26 2017-04-12 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
HK1206726A1 (en) 2012-03-19 2016-01-15 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
WO2016006975A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
KR20160007347A (ko) 2014-07-11 2016-01-20 에스티팜 주식회사 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
BR112018000254A2 (pt) 2015-07-07 2018-09-04 H Lundbeck As inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
AU2017292650A1 (en) 2016-07-06 2018-12-13 H. Lundbeck A/S PDE9 inhibitors for treatment of peripheral diseases
EP3529250B1 (en) 2016-10-18 2023-12-06 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
BR112018013084A2 (pt) 2016-10-28 2018-12-11 H Lundbeck As tratamentos de combinação compreendendo a administração de imidazopirazinonas
SG11201903770UA (en) 2016-10-28 2019-05-30 H Lundbeck As Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
ES2962865T3 (es) * 2016-11-18 2024-03-21 Integrative Res Laboratories Sweden Ab Nuevos derivados de azetidina útiles como moduladores de la neurotransmisión catecolaminérgica cortical
WO2018153887A1 (en) * 2017-02-23 2018-08-30 Boehringer Ingelheim International Gmbh New medical use of compound iii
SI3630772T1 (sl) 2017-05-26 2024-05-31 Cardurion Pharmaceuticals, Inc., Postopki izdelave in uporabe zaviralcev pde9
CN110003213B (zh) * 2018-01-04 2021-10-08 南京农业大学 苯并咪唑并三嗪酮类化合物、制备方法及应用
JP2021509669A (ja) 2018-01-05 2021-04-01 ディセルナ ファーマシューティカルズ インコーポレイテッド 免疫療法を強化するためのベータ−カテニン及びｉｄｏの発現の低減
EP3801526B1 (en) 2018-05-25 2023-12-27 Imara Inc. Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one
CN112996512B (zh) 2018-08-31 2025-01-03 卡都瑞恩医药公司 用于治疗镰状细胞病的pde9抑制剂
EP3965768A1 (en) * 2019-05-07 2022-03-16 Imara Inc. Pde9 inhibitors for treating thalassemia
CN113072556B (zh) * 2021-03-30 2022-02-01 牡丹江医学院 一种用于治疗胶质瘤的药物及其制备方法
JP2025538452A (ja) * 2022-11-15 2025-11-28 フリーダム・バイオサイエンシズ，インコーポレーテッド ９型ホスホジエステラーゼの阻害による特定の神経精神障害の治療または予防におけるセロトニン作動性幻覚薬の効力の増強

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200001338T2 (tr) 1997-11-12 2000-08-21 Bayer Aktiengesellschaft 2-Fenil-ikameli imidazotriazinonlar
WO2000043392A2 (de) 1999-01-20 2000-07-27 Arzneimittelwerk Dresden Gmbh Verwendung von imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als arzneimittel
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
JP2005508978A (ja) 2001-11-02 2005-04-07 ファイザー・プロダクツ・インク Ｐｄｅ９阻害薬によるインスリン抵抗性症候群及び２型糖尿病の治療
GB2388111A (en) 2002-05-01 2003-11-05 Bayer Ag Novel imidazotriazinone compounds
US6684626B1 (en) 2002-07-30 2004-02-03 General Electric Company Aircraft gas turbine engine with control vanes for counter rotating low pressure turbines
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
JP2007509923A (ja) 2003-10-31 2007-04-19 ファイザー・プロダクツ・インク 肥満関連状態の処置としてのホスホジエステラーゼ９阻害
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
WO2008072779A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. キノキサリン誘導体
MX2009011830A (es) * 2007-05-11 2009-11-13 Pfizer Compuestos amino-heterociclicos.
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
MX2010006388A (es) 2007-12-10 2010-06-25 Glaxo Group Ltd Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina.
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
US20110082147A1 (en) 2009-07-24 2011-04-07 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
AU2011305568B2 (en) * 2010-09-20 2015-12-10 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CN104093720B (zh) 2012-01-26 2017-04-12 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂

Also Published As

Publication number Publication date
EP2807163A1 (en) 2014-12-03
EP3178820A1 (en) 2017-06-14
PH12014501695A1 (en) 2014-10-20
CN104093720A (zh) 2014-10-08
WO2013110768A1 (en) 2013-08-01
US20160213674A1 (en) 2016-07-28
CN104093720B (zh) 2017-04-12
MX2014008912A (es) 2014-08-26
US9434733B2 (en) 2016-09-06
EP2807163B1 (en) 2017-03-22
AP2014007820A0 (en) 2014-07-31
MX351582B (es) 2017-10-20
US20150045348A1 (en) 2015-02-12
US9850249B2 (en) 2017-12-26
PH12014501695B1 (en) 2019-06-03
CN107082783A (zh) 2017-08-22
DOP2014000175A (es) 2014-08-31
US20170081333A1 (en) 2017-03-23
US9533992B2 (en) 2017-01-03
BR112014018199A8 (pt) 2021-03-02
CO7020913A2 (es) 2014-08-11
AU2017200886A1 (en) 2017-03-02
HK1199879A1 (en) 2015-07-24
SG11201403909RA (en) 2014-10-30
EP3178820B1 (en) 2017-12-20
AU2013213603A1 (en) 2014-07-24
ECSP14015609A (es) 2015-12-31
AU2017200886B2 (en) 2018-01-18
AU2013213603B2 (en) 2017-02-02
CN107082783B (zh) 2019-03-22

Similar Documents

Publication Publication Date Title
ECSP14015609A (es) Inhibidores de pde9 con estructura básica de imidazotriazinona
CR20120317A (es) Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a
JOP20180103A1 (ar) مركب صيدلاني
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
ECSP12011793A (es) Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, método para la preparación de los mismos y composición farmacéutica que los contiene
MY165087A (en) Neprilysin inhibitors
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
PH12015500260A1 (en) Neprilysin inhibitors
CR20120319A (es) Derivados de fenilimidazol heteroaromáticos como inhibidores de enzima pde10a
IN2015DN00185A (es)
PH12014502733A1 (en) Neprilysin inhibitors
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
MD20140136A2 (ro) Inhibitori ai virusului hepatic C
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
GEAP202413811A (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
PH12013501240A1 (en) Neprilysin inhibitors
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
MX354476B (es) Inhibidores de neprilisina.
ECSP14013239A (es) Composiciones farmacéuticas
WO2013003298A3 (en) Inhibitors of pde10
CR20120318A (es) Derivados de aril triazol heteroaromáticos como inhibidores de enzima pde10a
ECSP13012698A (es) Derivados de imidazol como inhibidores de la enzima pde10a
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
MX2013002656A (es) Nuevo proceso.